UNITY-NHL Trial in R/R FL and MZL
Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.
Watch
Role of Umbralisib in R/R FL and MZL
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review the tolerability and efficacy of umbralisib in the management of R/R FL and MZL.
Managing Adverse Events of PI3K Inhibitors in R/R FL and MZL
Expert hematologist/oncologists comment on the safety profile of PI3K inhibitors when treating R/R FL and MZL and share their approach to managing associated adverse events.
Role of PI3K Inhibitors in the Management of R/R FL and MZL
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review clinical trial data for idelalisib, copanlisib, and duvelisib and discuss their personal experience using these agents for the management of R/R FL and MZL.
Age-Related Characteristics Impact Outcomes in AML
Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.
Case 1: Treatment Recommendations for PD-L1+ TNBC
The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.
Case 2: Recurrence of HER2+ Breast Cancer After 12 Months
Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.
Case 1: KEYNOTE-355 Trial Design and Considerations
The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.
Case 2: Treatment Options at Recurrence of HER2+ Breast Cancer After 5 Years
The panel of experts in breast cancer discuss treatment options when the cancer has metastasized.
Case 1: IMpassion 130 Trial Design and Results
Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.
Case 1: 53-Year-Old Woman With TNBC
Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.
Case 2: Recurrence in High-Risk HR+/HER2+ Breast Cancer
Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.
Best Therapies for HER2+ Breast Cancer Are Also Best for Brain Metastases
Thomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.
Unmet Needs in Advanced or Metastatic TRK Fusion+ Thyroid Cancer
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.
Exploring Current and Future Treatment in Patients With DLBCL
Mitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.
monarchE Investigators Set Out to Make Practice-Changing Impact in Breast Cancer
Nadia Harbeck, MD, PhD, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib, will change breast cancer treatment.
Future Directions and Unmet Needs in the Treatment of R/R FL
Looking ahead, Loretta Nastoupil, MD, reviews the future direction and unmet needs in the management of relapsed/refractory follicular lymphoma (R/R FL).
Managing Side Effects of Tazemetostat in R/R FL
Dr Loretta Nastoupil describes best practices for managing the side effects of tazemetostat in patients with R/R FL.
Efficacy of tazemetostat in patients with EZH2m and EZH2wt R/R FL
Loretta Nastoupil, MD, discusses the use of tazemetostat in patients with and without an EZH2m.
Treatment Challenges Beyond the Second-line in R/R FL
Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.
Second-line Treatment Options for R/R FL Patients
Considerations for Therapy in R/R FL
A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.
First-line Therapy Options in ND Follicular Lymphoma
Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).
R/R FL Patient Case Review and Impressions
Loretta Nastoupil, MD, describes the role of molecular testing used in risk stratification of patient with FL
Case Presentation: Relapsed/Refractory Follicular Lymphoma
Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).
Clinical Trials with Early PI3K Inhibitors in R/R FL and MZL
Expert hematologist/oncologists discuss the use of early PI3K inhibitors in the management of R/R follicular lymphoma (FL) and MZL (marginal zone lymphoma).
Overview of PI3K Inhibition in Lymphoma
Ian W. Flinn, MD, PhD, leads the discussion on the various PI3K isoforms and their role in lymphoma.
Case 2: Considerations for Optimizing Therapy in High Risk MF
Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.
Case 2: Efficacy and Safety of Fedratinib in High Risk MF
Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.
Case 2: Safety and Efficacy of Ruxolitinib in High Risk MF
Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.